Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | ARNT | P27540 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559386 | 0.87 | AKR1B1 (0.77) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2646781 | 0.83 | AKR1B1 (0.70) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL13811262 | 0.82 | MAPK1 (0.75) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2641949 | 0.81 | AKR1B1 (0.69) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1668253 | 0.81 | AKR1B1 (0.69) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL8559459 | 0.81 | AKR1B1 (0.69) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL11468688 | 0.81 | AKR1B1 (0.72) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL8559703 | 0.80 | AKR1B1 (0.70) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL11392520 | 0.79 | MAPK1 (0.84) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16577821 | 0.79 | HCAR3 (0.70) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | AKR1B1 4341/4885AKR1C4 4497/4885AKR1C3 4439/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | AKR1B1 4341/4885AKR1C4 4497/4885AKR1C3 4439/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | AKR1B1 4341/4885AKR1C4 4497/4885AKR1C3 4439/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | AKR1B1 4341/4885AKR1C4 4497/4885AKR1C3 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.